Description

Strain Information

Former Names B6(C)-H2bm12/KhEgJ    (Changed: 12-SEP-05 ) B6.C-H2bm12/KhEgJ    (Changed: 01-SEP-05 ) Type Coisogenic; Mutant Strain; Spontaneous Mutation; Additional information on Genetically Engineered Mutant Mice. Mating System Homozygote x Homozygote         (Female x Male) Species laboratory mouse Background Strain C57BL/6KEg Donor Strain BALB/cKh Generation N10F67 (08-FEB-06)

Appearance
black
Related Genotype: a/a

Control Information

	Control
	000664 C57BL/6J
Considerations for Choosing Controls

Related Strains

Strains carrying   H2-Ab1^bm12 allele

003625

B6.C-H2-Ab1bm12/KhEg-Mc1re-J/J

View Strains carrying   H2-Ab1^bm12     (1 strain)

Strains carrying other alleles of H2-Ab1

002081	B6.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim/J
002956	B6NTac.Cg-H2-Ab1tm1Gru Tg(Ab1TL)1Gru/J
006021	NOD.Cg-H2-Ab1tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/EllJ
006023	NOD.Cg-H2-Ab1tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/EllJ
004256	NOD.Cg-H2-Ab1tm1Gru/Dvs
004606	NOD.Cg-Prkdcscid H2-Ab1tm1Doi Tg(HLA-DQA1,HLA-DQB1)1Dv/SzJ
005589	NOD.Cg-Prkdcscid H2-Ab1tm1Doi/SzJ
006024	NOD.Cg-Rag1tm1Mom H2-Ab1tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/EllJ
006022	NOD.Cg-Rag1tm1Mom H2-Ab1tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/EllJ
002031	SJL.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim/J

View Strains carrying other alleles of H2-Ab1     (10 strains)

Additional Web Information

Congenic Nomenclature
Genetic Quality Control Annual Report

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms

      assigned by genotype

H2-Ab1^bm12/H2-Ab1^bm12

        B6(C)-H2-Ab1^bm12/KhEgJ

• immune system phenotype
• abnormal T cell physiology (MGI Ref ID J:100123)
  • peptide-specific decrease in calcium flux, IFNG and IL10 production relative to H2^b
• abnormal level of surface class II molecules (MGI Ref ID J:100194)
  • Decreased levels of H2-Ab1 and greatly reduced levels of co-precipitating invariant chain were found in immunoprecipitations from bm12 homozygotes compared with C57BLKS controls
• decreased susceptibility to autoimmune disorder (MGI Ref ID J:100123)
• decreased susceptibility to experimental autoimmune myasthenia gravis (MGI Ref ID J:100213)
  • resistant to experimental autoimmune myasthenia gravis induced via standard protocol in C57BL/6J
• decreased susceptibility to parasitic infection (MGI Ref ID J:48242)
  • decreased susceptibility to Leishmania donovani relative to C57BL/6
• deviant class II histocompatibility locus (MGI Ref ID J:100015)

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

H2-Ab1^bm12/H2-Ab1^bm12

        NZB.B6(C)-H2-Ab1^bm12

• hematopoietic system phenotype
• decreased CD8-positive T cell number (MGI Ref ID J:4554)
  • decreased CD8 single positive splenic T cells
• hemolytic anemia (MGI Ref ID J:4554)
  • occurs in non-congenic NZB and NZB congenic for bm12, but not C57BL/6 bearing bm12 occurs in non-congenic NZB and NZB congenic for bm12, but not C57BL/6 bearing bm12
  • high titers of anti- double stranded DNA serum antiodies, with class switching from IgM to IgG by 4 months, present in both genders but higher in females, a phenotype not found in the NZB, NZB.B6-H2^b, or B6(C)-H2-Ab1^bm12 backgrounds high titers of anti- double stranded DNA serum antiodies, with class switching from IgM to IgG by 4 months, present in both genders but higher in females, a phenotype not found in the NZB, NZB.B6-H2^b, or B6(C)-H2-Ab1^bm12 backgrounds
• increased B cell number (MGI Ref ID J:104189)
  • increased CD5⁺ splenic B cells
• increased CD4-positive T cell number (MGI Ref ID J:4554)
  • increased CD4 single positive splenic T cells
• increased double-negative T cell number (MGI Ref ID J:4554)
  • increased double negative splenic T cells
• immune system phenotype
• abnormal immunoglobulin level (MGI Ref ID J:104189)
  • serum IgG and IgG2a are elevated relative to B6(C)-H2-Ab1^bm12 or NZB.B6-H2^b congenic mice
• abnormal level of surface class II molecules (MGI Ref ID J:104189)
  • staining of splenotycte MHC class II by antibody 25-5-165 is decreased relative to that on NZB.B6-H2^b splenocytes
• autoimmune response (MGI Ref ID J:4554)
  • natural thymocytotoxic autoantibodies are found in all non-congenic NZB, NZB congenic for H2-Ab1^bm12, but not C57BL/6 congenic for H2-Ab1^bm12 and only 36% of NZB congenic for H2^b natural thymocytotoxic autoantibodies are found in all non-congenic NZB, NZB congenic for H2-Ab1^bm12, but not C57BL/6 congenic for H2-Ab1^bm12 and only 36% of NZB congenic for H2^b
• increased anti-double stranded DNA antibody level (MGI Ref ID J:104189)
  • high titers of anti- double stranded DNA serum antiodies, with class switching from IgM to IgG by 4 months, present in both genders but higher in females, a phenotype not found in the NZB, NZB.B6-H2^b, or B6(C)-H2-Ab1^bm12 backgrounds
• increased anti-erythrocyte antigen antibody level (MGI Ref ID J:4554)
  • as in non-congenic NZB, but distinct from NZB congenic for H2^b, Coombs' test shows heightened anti-erythrocyte autoantibodies
• increased anti-single stranded DNA antibody level (MGI Ref ID J:104189)
  • high titers of anti- single strainded DNA IgG serum antibodies are found and appear earlier than in NZB background
• decreased CD8-positive T cell number (MGI Ref ID J:4554)
  • decreased CD8 single positive splenic T cells
• increased B cell number (MGI Ref ID J:104189)
  • increased CD5⁺ splenic B cells
• increased CD4-positive T cell number (MGI Ref ID J:4554)
  • increased CD4 single positive splenic T cells
• increased double-negative T cell number (MGI Ref ID J:4554)
  • increased double negative splenic T cells
• homeostasis/metabolism phenotype
• abnormal response/metabolism to endogenous compounds (MGI Ref ID J:104189)
  • do not respond to beef or porcine insulin, both of which the parental NZB responds to while NZB.B6-H2^b congenic mice respond to beef insulin but not porcine insulin
• proteinuria (MGI Ref ID J:104189)
  • more severe in females than males and not found in NZB or NZB.B6-H2^b
• life span-post-weaning/aging
• premature death (MGI Ref ID J:104189)
  • mean survival 7.1 months is much less than that of NZB or NZB.B6-H2^b
• renal/urinary system phenotype
• proteinuria (MGI Ref ID J:104189)
  • more severe in females than males and not found in NZB or NZB.B6-H2^b

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

H2-Ab1^bm12 related

Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers

Genes & Alleles

Gene & Allele Information

Allele Symbol		H2-Ab1bm12
Allele Name		b haplotype mutation 12
Allele Type		Spontaneous
Common Name(s)		H-2bm; H2bm12;
Strain of Origin		(C57BL/6 x BALB/c)F1
Gene Symbol and Name		H2-Ab1, histocompatibility 2, class II antigen A, beta 1
Chromosome		17
Gene Common Name(s)		A beta; AI845868; Abeta; CELIAC1; H-2Ab; H2-Ab; HLA-DQB; I-Ab; I-Abeta; I-region-associated antigen 2; IAb; IDDM1; Ia-2; Ia2; Rmcs1; expressed sequence AI845868; histocompatibility 2, class II antigen A, beta; response to metastatic cancers 1;
General Note		Genbank ID for this allele: M54876
Molecular Note		Three non-consecutive nucleotide changes occurred, resulting in three amino acid substitutions in the beta1 exon. The amino acid changes consist of codon 67 (isoleucine to phenylalanine), codon 70 (arginine to glutamine) and codon 71 (threonine to lysine). These changes were likely the product of gene conversion of H2-Ab1b with sequence from H2-Ebb. [MGI Ref ID J:100015] [MGI Ref ID J:109266] [MGI Ref ID J:99766] [MGI Ref ID J:99767]

Genotyping

Genotyping Information

This strain will not have a genotyping protocol or one is not currently available.

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Silverman RH; Zhou A; Auerbach MB; Kish D; Gorbachev A; Fairchild RL. 2002. Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2',5'-oligoadenylate-dependent RNase L. Viral Immunol 15(1):77-83. [PubMed: 11952148]  [MGI Ref ID J:109855]

Additional References

H2-Ab1^bm12 related

Anderson BE; Taylor PA; McNiff JM; Jain D; Demetris AJ; Panoskaltsis-Mortari A; Ager A; Blazar BR; Shlomchik WD; Shlomchik MJ. 2008. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 111(10):5242-51. [PubMed: 18285547]  [MGI Ref ID J:135662]

Ardehali A; Fischbein MP; Yun J; Irie Y; Fishbein MC; Laks H. 2002. Indirect alloreactivity and chronic rejection. Transplantation 73(11):1805-7. [PubMed: 12085005]  [MGI Ref ID J:77397]

Blazar BR; Carreno BM; Panoskaltsis-Mortari A; Carter L; Iwai Y; Yagita H; Nishimura H; Taylor PA. 2003. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171(3):1272-7. [PubMed: 12874215]  [MGI Ref ID J:120213]

Brown GR; Lee EL; El-Hayek J; Kintner K; Luck C. 2005. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol 174(8):4688-95. [PubMed: 15814693]  [MGI Ref ID J:109999]

Brown GR; Thiele DL. 2000. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions Eur J Immunol 30(10):2900-7. [PubMed: 11069072]  [MGI Ref ID J:65234]

Chiang BL; Bearer E; Ansari A; Dorshkind K; Gershwin ME. 1990. The BM12 mutation and autoantibodies to dsDNA in NZB.H-2bm12 mice. J Immunol 145(1):94-101. [PubMed: 2358682]  [MGI Ref ID J:104189]

Choudhury A; Maldonado MA; Cohen PL; Eisenberg RA. 2005. The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 174(12):7600-9. [PubMed: 15944260]  [MGI Ref ID J:100787]

Christadoss P; Lindstrom JM; Melvold RW; Talal N. 1985. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics 21(1):33-8. [PubMed: 3917973]  [MGI Ref ID J:100213]

Cohen PL; Creech E; Nakul-Aquaronne D; McDaniel R; Ackler S; Rapoport RG; Sobel ES; Eisenberg RA. 1993. Antigen nonspecific effect of major histocompatibility complex haplotype on autoantibody levels in systemic lupus erythematosus-prone lpr mice. J Clin Invest 91(6):2761-8. [PubMed: 7685774]  [MGI Ref ID J:12587]

Denaro M; Hammerling U; Rask L; Peterson PA. 1984. The Eb beta gene may have acted as the donor gene in a gene conversion-like event generating the Abm 12 beta mutant. EMBO J 3(9):2029-32. [PubMed: 6436017]  [MGI Ref ID J:99766]

Erlebacher A; Vencato D; Price KA; Zhang D; Glimcher LH. 2007. Constraints in antigen presentation severely restrict T cell recognition of the allogeneic fetus. J Clin Invest 117(5):1399-411. [PubMed: 17446933]  [MGI Ref ID J:122071]

Fischbein MP; Ardehali A; Yun J; Schoenberger S; Laks H; Irie Y; Dempsey P; Cheng G; Fishbein MC; Bonavida B. 2000. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol 165(12):7316-22. [PubMed: 11120867]  [MGI Ref ID J:118395]

Ford MS; Young KJ; Zhang Z; Ohashi PS; Zhang L. 2002. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med 196(2):261-7. [PubMed: 12119351]  [MGI Ref ID J:120698]

Gavin MA; Clarke SR; Negrou E; Gallegos A; Rudensky A. 2002. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 3(1):33-41. [PubMed: 11740498]  [MGI Ref ID J:109187]

Graubert TA; DiPersio JF; Russell JH; Ley TJ. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100(4):904-11. [PubMed: 9259590]  [MGI Ref ID J:42355]

Gur H; Mendel I; Kerlero de Rosbo N; Ben-Nun A. 1999. Effect of the bm12 class II mutation on proliferative and cytokine responses of encephalitogenic T cells in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis. J Autoimmun 13(1):3-10. [PubMed: 10441162]  [MGI Ref ID J:56654]

Hansen TH; Melvold RW; Arn JS; Sachs DH. 1980. Evidence for mutation in an I-A gene. Nature 285(5763):340-1. [PubMed: 7374785]  [MGI Ref ID J:99769]

Huygen K; Drowart A; Harboe M; ten Berg R; Cogniaux J; Van Vooren JP. 1993. Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCG. Infect Immun 61(6):2687-93. [PubMed: 8500908]  [MGI Ref ID J:13022]

Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA. 1992. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. J Immunol 148(11):3385-90. [PubMed: 1375242]  [MGI Ref ID J:1026]

Karachunski PI; Ostlie N; Bellone M; Infante AJ; Conti-Fine BM. 1995. Mechanisms by which the I-ABM12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. Scand J Immunol 42(2):215-25. [PubMed: 7631155]  [MGI Ref ID J:29106]

Klein J; Figueroa F; David CS. 1983. H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics 17(6):553-96. [PubMed: 6407984]  [MGI Ref ID J:7097]

Kosuge H; Suzuki J; Haraguchi G; Koga N; Maejima Y; Inobe M; Isobe M; Uede T. 2006. Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol 26(12):2660-5. [PubMed: 16990558]  [MGI Ref ID J:128034]

Kraj P; Pacholczyk R; Ignatowicz L. 2001. Alpha beta TCRs differ in the degree of their specificity for the positively selecting MHC/peptide ligand. J Immunol 166(4):2251-9. [PubMed: 11160279]  [MGI Ref ID J:126970]

Krco CJ; Beito TG; David CS. 1992. Determination of tolerance to self E alpha peptides by clonal elimination of H-2E reactive T cells and antigen presentation by H-2A molecules. Transplantation 54(5):920-3. [PubMed: 1440860]  [MGI Ref ID J:3237]

Lamouse-Smith E; McCarthy SA. 1997. Allospecific cytotoxic T cells generated from beta 2m-/- mice in primary MLC: analysis of activation requirements, specificity, and phenotype. Cell Immunol 179(2):107-15. [PubMed: 9268494]  [MGI Ref ID J:42696]

Le Moine A; Flamand V; de Lavareille A; Paulart F; Buonocore S; Vanderhaeghen ML; Nagy N; Habran C; Kiss R; Abramowicz D; Goldman M. 2002. Hypereosinophilic syndrome induced by neonatal immunization against MHC class II alloantigen: critical role of IL-4. Eur J Immunol 32(1):174-81. [PubMed: 11754358]  [MGI Ref ID J:73934]

Le Moine A; Surquin M; Demoor FX; Noel JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D. 1999. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. J Immunol 163(7):3778-84. [PubMed: 10490975]  [MGI Ref ID J:118717]

Leibnitz RR; Lipsky PE; Thiele DL. 1995. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides. J Immunol 155(4):1784-95. [PubMed: 7636234]  [MGI Ref ID J:28656]

Ma Z; Chen F; Madaio MP; Cohen PL; Eisenberg RA. 2006. Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J Immunol 177(10):7444-50. [PubMed: 17082664]  [MGI Ref ID J:139428]

Ma Z; Choudhury A; Kang SA; Monestier M; Cohen PL; Eisenberg RA. 2008. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 127(2):168-75. [PubMed: 18325838]  [MGI Ref ID J:133606]

Maeda Y; Reddy P; Lowler KP; Liu C; Bishop DK; Ferrara JL. 2005. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood 106(2):749-55. [PubMed: 15797996]  [MGI Ref ID J:107458]

McIntyre KR; Seidman JG. 1984. Nucleotide sequence of mutant I-A beta bm12 gene is evidence for genetic exchange between mouse immune response genes. Nature 308(5959):551-3. [PubMed: 6324001]  [MGI Ref ID J:100015]

McKean DJ; Melvold RW; David C. 1981. Tryptic peptide comparison of Ia antigen alpha and beta polypeptides from the I-A mutant B6.C-H-2bm12 and its congenic parental strain B6. Immunogenetics 14(1-2):41-51. [PubMed: 6948771]  [MGI Ref ID J:100194]

McKenzie IF; Morgan GM; Sandrin MS; Michaelides MM; Melvold RW; Kohn HI. 1979. B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse. J Exp Med 150(6):1323-38. [PubMed: 159937]  [MGI Ref ID J:99770]

Melvold RW; Wang K; Kohn HI. 1997. Histocompatibility gene mutation rates in the mouse: a 25-year review. Immunogenetics 47(1):44-54. [PubMed: 9382920]  [MGI Ref ID J:44711]

Mendel I; Gur H; Kerlero de Rosbo N; Ben-Nun A. 1999. Experimental autoimmune encephalomyelitis induced in B6.C-H-2bm12 mice by myelin oligodendrocyte glycoprotein: effect of MHC class II mutation on immunodominant epitope selection and fine epitope specificity of encephalitogenic T cells. J Neuroimmunol 96(1):9-20. [PubMed: 10227420]  [MGI Ref ID J:100211]

Mengle-Gaw L; Conner S; McDevitt HO; Fathman CG. 1984. Gene conversion between murine class II major histocompatibility complex loci. Functional and molecular evidence from the bm 12 mutant. J Exp Med 160(4):1184-94. [PubMed: 6434690]  [MGI Ref ID J:109266]

Nagano H; Mitchell RN; Taylor MK; Hasegawa S; Tilney NL; Libby P. 1997. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 100(3):550-7. [PubMed: 9239401]  [MGI Ref ID J:42090]

Naiki M; Yoshida SH; Ansari AA; Bill J; Gershwin ME. 1994. Activation of autoreactive T-cell clones from NZB.H-2bm12 mice. J Autoimmun 7(3):275-90. [PubMed: 7916904]  [MGI Ref ID J:18680]

Naiki M; Yoshida SH; Watanabe Y; Izui S; Ansari AA; Gershwin ME. 1993. The contribution of I-Abm12 to phenotypic and functional alterations among T-cell subsets in NZB mice. J Autoimmun 6(2):131-43. [PubMed: 8388689]  [MGI Ref ID J:4554]

Noorchashm H; Reed AJ; Rostami SY; Mozaffari R; Zekavat G; Koeberlein B; Caton AJ; Naji A. 2006. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 177(11):7715-22. [PubMed: 17114442]  [MGI Ref ID J:140848]

Oshima M; Yokoi T; Deitiker P; Atassi MZ. 1998. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis ofautoimmune T-cell responses against receptor degradation products. Autoimmunity 27(2):79-90. [PubMed: 9583739]  [MGI Ref ID J:46878]

Poulin LF; Habran C; Stordeur P; Goldman M; McKenzie A; Van Snick J; Renauld JC; Braun MY. 2005. Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells. Eur Cytokine Netw 16(3):233-9. [PubMed: 16266865]  [MGI Ref ID J:115764]

Poussin MA; Fuller CL; Goluszko E; Reyes VE; Braciale VL; Christadoss P. 2003. Suppressed clinical experimental autoimmune myasthenia gravis in bm12 mice is linked to reduced intracellular calcium mobilization and IL-10 and IFN-gamma release by acetylcholine receptor-specific T cells. J Neuroimmunol 134(1-2):104-10. [PubMed: 12507777]  [MGI Ref ID J:100123]

Poussin MA; Tuzun E; Goluszko E; Scott BG; Yang H; Franco JU; Christadoss P. 2003. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis. J Immunol 170(8):4389-96. [PubMed: 12682276]  [MGI Ref ID J:125435]

Ronchese F; Brown MA; Germain RN. 1987. Structure-function analysis of the Abm12 beta mutation using site-directed mutagenesis and DNA-mediated gene transfer. J Immunol 139(2):629-38. [PubMed: 3110276]  [MGI Ref ID J:99829]

Rosenberg AS; Sechler JM; Horvath JA; Maniero TG; Bloom ET. 1994. Assessment of alloreactive T cell subpopulations of aged mice in vivo. CD4+ but not CD8+ T cell-mediated rejection response declines with advanced age [published erratum appears in Eur J Immunol 1994 Oct;24(10):2571] Eur J Immunol 24(6):1312-6. [PubMed: 7911422]  [MGI Ref ID J:18905]

Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH. 2005. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 174(6):3408-15. [PubMed: 15749874]  [MGI Ref ID J:97695]

Sandner SE; Salama AD; Houser SL; Palmer E; Turka LA; Sayegh MH. 2003. New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant 3(10):1242-50. [PubMed: 14510697]  [MGI Ref ID J:133237]

Sarafova SD; Erman B; Yu Q; Van Laethem F; Guinter T; Sharrow SO; Feigenbaum L; Wildt KF; Ellmeier W; Singer A. 2005. Modulation of coreceptor transcription during positive selection dictates lineage fate independently of TCR/coreceptor specificity. Immunity 23(1):75-87. [PubMed: 16039581]  [MGI Ref ID J:100541]

Selvaggi G; Ricordi C; Podack ER; Inverardi L. 1996. The role of the perforin and Fas pathways of cytotoxicity in skin graft rejection. Transplantation 62(12):1912-5. [PubMed: 8990386]  [MGI Ref ID J:37400]

Sen E; Roy S. 1998. Immunobiological studies on experimental visceral Leishmaniasis. V. The I-A(Bm12) mutation specifies resistance to infection. Scand J Immunol 47(5):431-5. [PubMed: 9627126]  [MGI Ref ID J:48242]

Serody JS; Burkett SE; Panoskaltsis-Mortari A; Ng-Cashin J; McMahon E; Matsushima GK; Lira SA; Cook DN; Blazar BR. 2000. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease Blood 96(9):2973-80. [PubMed: 11049973]  [MGI Ref ID J:65501]

Serody JS; Cook DN; Kirby SL; Reap E; Shea TC; Frelinger JA. 1999. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 93(1):43-50. [PubMed: 9864144]  [MGI Ref ID J:51842]

Shao WH; Eisenberg RA; Cohen PL. 2008. The Mer receptor tyrosine kinase is required for the loss of B cell tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus. J Immunol 180(11):7728-35. [PubMed: 18490777]  [MGI Ref ID J:136377]

Sheng B; Odebralski JM; Smith RT. 1998. All or none peripheral tolerance induction in H-Y antigen-specific TCR transgenic mice. Transpl Immunol 6(2):78-83. [PubMed: 9777695]  [MGI Ref ID J:127670]

Tanaka M; Sydow K; Gunawan F; Jacobi J; Tsao PS; Robbins RC; Cooke JP. 2005. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112(11):1549-56. [PubMed: 16144995]  [MGI Ref ID J:118229]

Tomura M; Nakatani I; Murachi M; Tai XG; Toyo-oka K; Fujiwara H. 1997. Suppression of allograft responses induced by interleukin-6, which selectively modulates interferon-gamma but not interleukin-2 production. Transplantation 64(5):757-63. [PubMed: 9311716]  [MGI Ref ID J:43100]

Ueno T; Habicht A; Clarkson MR; Albin MJ; Yamaura K; Boenisch O; Popoola J; Wang Y; Yagita H; Akiba H; Ansari MJ; Yang J; Turka LA; Rothstein DM; Padera RF; Najafian N; Sayegh MH. 2008. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 118(2):742-51. [PubMed: 18172549]  [MGI Ref ID J:131045]

Varona R; Cadenas V; Gomez L; Martinez-A C; Marquez G. 2005. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 106(1):18-26. [PubMed: 15774622]  [MGI Ref ID J:107449]

Watanabe T; Kawamura T; Kawamura H; Haga M; Shirai K; Watanabe H ; Eguchi S ; Abo T. 1997. Intermediate TCR cells in mouse lung: their effector function to induce pneumonitis in mice with autoimmune-like graft-versus-host disease. J Immunol 158(12):5805-14. [PubMed: 9190932]  [MGI Ref ID J:40937]

Watanabe Y; Yoshida SH; Ansari AA; Gershwin ME. 1994. The contribution of H-2bm12 and non H-2 background genes on murine lupus in NZB.H-2bm12/b mice. J Autoimmun 7(2):153-64. [PubMed: 8037836]  [MGI Ref ID J:17841]

Widera G; Flavell RA. 1984. The nucleotide sequence of the murine I-E beta b immune response gene: evidence for gene conversion events in class II genes of the major histocompatibility complex. EMBO J 3(6):1221-5. [PubMed: 6086309]  [MGI Ref ID J:99767]

Xing Y; Sonner JM; Eger EI 2nd; Cascio M; Sessler DI. 2004. Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. Anesthesiology 101(2):544-6. [PubMed: 15277941]  [MGI Ref ID J:105413]

Yamada A; Salama AD; Sho M; Najafian N; Ito T; Forman JP; Kewalramani R; Sandner S; Harada H; Clarkson MR; Mandelbrot DA; Sharpe AH; Oshima H; Yagita H; Chalasani G; Lakkis FG; Auchincloss H Jr; Sayegh MH. 2005. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol 174(3):1357-64. [PubMed: 15661893]  [MGI Ref ID J:136519]

Yang B; McIntosh KR; Drachman DB. 1998. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin Immunol Immunopathol 86(1):45-58. [PubMed: 9434796]  [MGI Ref ID J:45094]

Yoshimoto T; Min B; Sugimoto T; Hayashi N; Ishikawa Y; Sasaki Y; Hata H; Takeda K; Okumura K; Van Kaer L; Paul WE; Nakanishi K. 2003. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med 197(8):997-1005. [PubMed: 12695491]  [MGI Ref ID J:120694]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           MP19

Colony Maintenance

Mating System	Homozygote x Homozygote         (Female x Male)
Diet Information	LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Supply Details

Standard Supply	Level 2. Up to 100 mice. Larger quantities or custom orders arranged upon request.
Supply Notes	Shipped at a specific age in weeks. Mice at a precise age in days, littermates and retired breeders are also available. Strains that must be genotyped are not available until five to seven weeks of age. Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

	Control
	000664 C57BL/6J
Considerations for Choosing Controls
USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions

See Terms of Use

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering and Purchasing Information

      Purchasing Information
      JAX^® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.